SCHEMBL30794990

SCHEMBL30794990

CCSc1nc(N2CCC2)cc(C)c1C(=O)NCc1cccc(F)c1

nearest known ligand 0.45

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.45
LMNA P02545 4/20 0.43
POLB P06746 2/20 0.43
TP53 P04637 3/20 0.43
ALDH1A1 P00352 1/20 0.42
HPGD P15428 1/20 0.42
MAPT P10636 2/20 0.42
CHRM4 P08173 1/20 0.41
SCD O00767 1/20 0.41
THRB P10828 1/20 0.41
GAA P10253 1/20 0.41
MAOB P27338 1/20 0.40
RET P07949 1/20 0.40
CALCA P06881 1/20 0.40
EPHX2 P34913 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2131351 1.00 SMN1; SMN2 (0.45) SMN1; SMN2LMNAPOLBTP53ALDH1A1
SCHEMBL30794366 0.98 SMN1; SMN2 (0.47) SMN1; SMN2LMNAPOLBTP53ALDH1A1
SCHEMBL2131491 0.98 SMN1; SMN2 (0.47) SMN1; SMN2LMNAPOLBTP53ALDH1A1
SCHEMBL2130250 0.97 SMN1; SMN2 (0.49) SMN1; SMN2LMNAPOLBTP53ALDH1A1
SCHEMBL2130537 0.97 SMN1; SMN2 (0.49) SMN1; SMN2LMNAPOLBTP53ALDH1A1
SCHEMBL30795097 0.97 SMN1; SMN2 (0.49) SMN1; SMN2LMNAPOLBTP53ALDH1A1
SCHEMBL30796336 0.97 SMN1; SMN2 (0.49) SMN1; SMN2LMNAPOLBTP53ALDH1A1
SCHEMBL30794521 0.93 SRC (0.44) SMN1; SMN2LMNAPOLBTP53ALDH1A1
SCHEMBL2129031 0.93 SRC (0.44) SMN1; SMN2LMNAPOLBTP53ALDH1A1
SCHEMBL2130990 0.93 RET (0.46) SMN1; SMN2TP53MAPTCHRM4SCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4584250-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS Biohaven Therapeutics Ltd. (VG) 2025-07-16 EP disclosed
EP-4580679-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS Biohaven Therapeutics Ltd. (VG) 2025-07-09 EP disclosed
WO-2024054811-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 WO disclosed
WO-2024054807-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 WO disclosed
WO-2024050389-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-07 WO disclosed